Racial and ethnic disparities among participants in precision oncology clinical studies. A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results